BR112013004662A2 - agonistas de receptores de neurotrofina e o uso destes como medicamentos - Google Patents
agonistas de receptores de neurotrofina e o uso destes como medicamentosInfo
- Publication number
- BR112013004662A2 BR112013004662A2 BR112013004662A BR112013004662A BR112013004662A2 BR 112013004662 A2 BR112013004662 A2 BR 112013004662A2 BR 112013004662 A BR112013004662 A BR 112013004662A BR 112013004662 A BR112013004662 A BR 112013004662A BR 112013004662 A2 BR112013004662 A2 BR 112013004662A2
- Authority
- BR
- Brazil
- Prior art keywords
- medicines
- receptor agonists
- neurotrophin receptor
- neurotrophin
- agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37882310P | 2010-08-31 | 2010-08-31 | |
| US61/378,823 | 2010-08-31 | ||
| PCT/IB2011/002562 WO2012028959A1 (en) | 2010-08-31 | 2011-08-31 | Agonists of neurotrophin receptors and their use as medicaments |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112013004662A2 true BR112013004662A2 (pt) | 2016-08-02 |
| BR112013004662B1 BR112013004662B1 (pt) | 2021-09-28 |
| BR112013004662B8 BR112013004662B8 (pt) | 2021-12-28 |
Family
ID=45048148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013004662A BR112013004662B8 (pt) | 2010-08-31 | 2011-08-31 | Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8791076B2 (pt) |
| EP (1) | EP2611775B8 (pt) |
| JP (1) | JP5946454B2 (pt) |
| KR (1) | KR101964954B1 (pt) |
| CN (1) | CN103270022B (pt) |
| AU (1) | AU2011298091B2 (pt) |
| BR (1) | BR112013004662B8 (pt) |
| CA (1) | CA2809774C (pt) |
| DK (1) | DK2611775T3 (pt) |
| ES (1) | ES2575684T3 (pt) |
| HR (1) | HRP20160553T1 (pt) |
| HU (1) | HUE029393T2 (pt) |
| IL (1) | IL224972A (pt) |
| MX (1) | MX340233B (pt) |
| PL (1) | PL2611775T3 (pt) |
| PT (1) | PT2611775E (pt) |
| RU (1) | RU2606622C2 (pt) |
| SI (1) | SI2611775T1 (pt) |
| WO (1) | WO2012028959A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289886A1 (en) * | 2009-08-31 | 2011-03-02 | Institut d'Investigacions Biomédiques August PI I Sunyer | Peptoid agonists of nerve growth factor and their use as medicaments |
| HUE029393T2 (en) | 2010-08-31 | 2017-03-28 | Bionure Farma S L | Neurotrophin receptor agonists and their use as medicaments |
| WO2014100433A1 (en) * | 2012-12-19 | 2014-06-26 | Brown University | Methods for treatment of microcephaly associated autism disorders |
| EP2950095B1 (en) * | 2014-05-28 | 2018-08-29 | Technische Universität Dresden | Cell-based assay and screening methods for modulators of p75NTR signaling |
| EP3504209A4 (en) * | 2016-08-25 | 2020-04-29 | Pharmatrophix Inc. | METHODS AND LINKS FOR TREATING ALCOHOL CONSUMPTION-RELATED DISEASES |
| KR101821118B1 (ko) | 2016-09-06 | 2018-01-23 | 가톨릭대학교 산학협력단 | 감보그 산(gambogic acid)을 포함한 알러지성 질환 예방 또는 치료용 조성물 |
| CN107802823A (zh) * | 2017-10-27 | 2018-03-16 | 胡军 | Sh2b衔接蛋白1在治疗帕金森病中的功能应用 |
| EP3823674A4 (en) * | 2018-07-18 | 2022-12-28 | Manzanita Pharmaceuticals, Inc. | CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF |
| BR112021010704A2 (pt) | 2018-12-05 | 2021-08-24 | Scohia Pharma, Inc. | Composto macrocíclico e uso do mesmo |
| TW202116297A (zh) * | 2019-07-03 | 2021-05-01 | 西班牙商布爾奴爾法碼有限公司 | 組合療法之方法、組成物與套組 |
| TW202131914A (zh) | 2019-10-30 | 2021-09-01 | 西班牙商布爾奴爾法碼有限公司 | 用於神經疾病或病狀的治療之新治療方案 |
| WO2024133860A1 (en) * | 2022-12-22 | 2024-06-27 | Oculis Operations Sàrl | Synthesis of small molecule agonists of neuroptrophin |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU189214B (en) | 1983-01-20 | 1986-06-30 | Alkaloida Vegyeszeti Gyar,Hu | Process for preparing pyrroline and pyrrolidine carboxamide derivatives |
| US6271205B1 (en) | 1994-09-21 | 2001-08-07 | University Of Massachusetts Medical Center | Cancer treatment by expression of differentiation factor receptor |
| US5747458A (en) | 1995-06-07 | 1998-05-05 | Chiron Corporation | Urokinase receptor ligands |
| US6391871B1 (en) | 1996-09-20 | 2002-05-21 | John W. Olney | Preventing neuronal degeneration in Alzheimer's disease |
| DE19751062A1 (de) | 1997-11-18 | 1999-07-08 | Univ Ludwigs Albert | An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels |
| US6124361A (en) | 1997-12-31 | 2000-09-26 | Pfizer Inc | Bicyclo[3.1.0]hexanes and related compounds |
| EA005677B1 (ru) | 2000-05-04 | 2005-04-28 | Басф Акциенгезельшафт | Гетероциклилзамещенные фенилсульфамоилкарбоксамиды |
| ES2169690B1 (es) * | 2000-10-06 | 2004-03-16 | Diverdrugs Sl | Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen. |
| ES2169691B1 (es) * | 2000-10-11 | 2004-03-16 | Diverdrugs Sl | Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen. |
| AU2003280117B2 (en) | 2002-11-20 | 2009-09-10 | Newron Sweden Ab | Compounds and methods for increasing neurogenesis |
| DE10303229B4 (de) | 2003-01-28 | 2007-07-26 | Keyneurotek Ag | Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen |
| US20110052603A1 (en) | 2006-10-06 | 2011-03-03 | The Walter And Eliza Hall Institute Of Medical Research | method of treatment and agents useful for same |
| EP1994944A1 (en) * | 2007-05-21 | 2008-11-26 | Laboratorios SALVAT, S.A. | Polymer conjugate compounds for the inhibition of apoptosis |
| AU2009297626B2 (en) | 2008-09-24 | 2016-01-14 | Fujimoto Pharmaceutical Corporation | Aptamer for NGF and use thereof |
| RU2410392C2 (ru) * | 2009-02-16 | 2011-01-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН | Дипептидные миметики нейротрофинов ngf и bdnf |
| EP2289882A1 (en) | 2009-08-31 | 2011-03-02 | Institut d'Investigacions Biomédiques August PI I Sunyer | 3-oxopiperazinium derivatives as agonists of nerve growth factor and their use as medicaments |
| EP2289886A1 (en) | 2009-08-31 | 2011-03-02 | Institut d'Investigacions Biomédiques August PI I Sunyer | Peptoid agonists of nerve growth factor and their use as medicaments |
| HUE029393T2 (en) | 2010-08-31 | 2017-03-28 | Bionure Farma S L | Neurotrophin receptor agonists and their use as medicaments |
-
2011
- 2011-08-31 HU HUE11788579A patent/HUE029393T2/en unknown
- 2011-08-31 CA CA2809774A patent/CA2809774C/en active Active
- 2011-08-31 KR KR1020137008259A patent/KR101964954B1/ko active IP Right Grant
- 2011-08-31 EP EP11788579.8A patent/EP2611775B8/en active Active
- 2011-08-31 DK DK11788579.8T patent/DK2611775T3/en active
- 2011-08-31 ES ES11788579.8T patent/ES2575684T3/es active Active
- 2011-08-31 PT PT117885798T patent/PT2611775E/pt unknown
- 2011-08-31 SI SI201130839A patent/SI2611775T1/sl unknown
- 2011-08-31 JP JP2013526566A patent/JP5946454B2/ja active Active
- 2011-08-31 PL PL11788579.8T patent/PL2611775T3/pl unknown
- 2011-08-31 BR BR112013004662A patent/BR112013004662B8/pt active IP Right Grant
- 2011-08-31 MX MX2013002329A patent/MX340233B/es active IP Right Grant
- 2011-08-31 CN CN201180049622.8A patent/CN103270022B/zh active Active
- 2011-08-31 US US13/223,166 patent/US8791076B2/en active Active
- 2011-08-31 AU AU2011298091A patent/AU2011298091B2/en active Active
- 2011-08-31 WO PCT/IB2011/002562 patent/WO2012028959A1/en active Application Filing
- 2011-08-31 RU RU2013113634A patent/RU2606622C2/ru active
-
2013
- 2013-02-28 IL IL224972A patent/IL224972A/en active IP Right Grant
-
2014
- 2014-06-11 US US14/301,981 patent/US9453047B2/en active Active
-
2016
- 2016-05-23 HR HRP20160553TT patent/HRP20160553T1/hr unknown
- 2016-09-09 US US15/261,410 patent/US10106577B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013004662A2 (pt) | agonistas de receptores de neurotrofina e o uso destes como medicamentos | |
| CR20150380A (es) | Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico | |
| BR112012013148A2 (pt) | formulação farmacêutica e uso | |
| CO6862157A2 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimida y su uso como moduladores de receptoresde c5a | |
| BRPI1010533A2 (pt) | tetrahidroazolopirazinas sulfoniladas e seu uso como medicamentos | |
| BR112014014763A8 (pt) | novos conjugados de anticorpo-medicamento (adcs) e uso dos mesmos | |
| BR112012021065A2 (pt) | artigo de uso descartável | |
| BR112013007506A2 (pt) | piridinonas/pirazinonas - métodos de criação e de uso | |
| BR112013016030A2 (pt) | compostos e seu uso como inibidores de bace | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| BRPI1012533A2 (pt) | composto de piradazinona e uso do mesmo | |
| BR112012020718A2 (pt) | complexo de metal-ligante e catalisador | |
| BR112013013132A2 (pt) | adaptador e dispositivo de aplicação de fármaco | |
| BR112013014321A2 (pt) | moduladores inovadores e métodos de uso | |
| BR112012031232A2 (pt) | método, dispositivo e uso | |
| BRPI0911563A2 (pt) | uso de antagonista da progesterona | |
| DK3222272T3 (da) | Farmaceutisk sammensætning med carbetocin | |
| BRPI1010024A2 (pt) | derivados de aminopirrolidinona e uso dos mesmos | |
| CO7000778A2 (es) | Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico | |
| BR112012001797A2 (pt) | composto bicíclico e uso do mesmo para propósitos médicos | |
| CO6781486A2 (es) | Compuestos y su uso | |
| BR112013008605A2 (pt) | aparelho de trabalho móvel com construção de suporte | |
| BR112013013633A2 (pt) | derivados de alquina e alceno como moduladores do receptor de esfingosina 1-fosfato-1 | |
| BR112013000356A2 (pt) | formulação farmacêutica injetável de malfalano | |
| BRPI1011036A2 (pt) | uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: BIONURE FARMA, S.L. (ES) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: BIONURE FARMA, S.L. (ES) , INSTITUT D'INVESTIGACIO |
|
| B25D | Requested change of name of applicant approved |
Owner name: BIONURE FARMA, S.L. (ES) ; CONSEJO SUPERIOR DE INV |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/08/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2647, QUANTO AO ENDERECO DE UM DOS TITULARES |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2647, QUANTO AO ENDERECO DE UM DOS TITULARES |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2647 DE 28/09/2021 QUANTO AO ENDERECO. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2647, QUANTO AOS NOMES DOS TITULARES |